SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

XEN1720

XENE·Xenon Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Not stated
Time to market
Not stated
Why 2/10
No hard, dated catalyst is scheduled for XEN1720 in the next ~12 months. The drug is not mentioned in any public pipeline disclosure, SEC filing, or clinical trial registry, and appears to be a preclinical or early discovery-stage program with no publicly announced development timeline.
Actionable Insight NEUTRAL

XEN1720 is not a publicly disclosed development candidate. Xenon's pipeline is focused on azetukalner (epilepsy NDA submitted, depression Phase 3 data due December 2026) and two pain candidates (XEN1701, XEN1120) advancing to Phase 2. Until Xenon formally discloses XEN1720 as a named program, there is no actionable catalyst to track for this molecule.

Price Chart

Loading chart...

Executive Summary

XEN1720 is not a publicly identified development candidate from Xenon Pharmaceuticals (XENE). Extensive searches of web news, SEC filings, ClinicalTrials.gov, press releases, and SecBot's internal databases found zero mentions of XEN1720 as an active drug program. Xenon's disclosed pipeline consists of azetukalner (XEN1101, its lead Kv7 potassium channel opener for epilepsy and depression), XEN1701 and XEN1120 (NaV1.7 pain candidates advancing to Phase 2), and earlier programs XEN496 and XEN901. The "XEN1720" designation does not correspond to any named compound in the company's public disclosures. It may be an internal research code for a very early discovery-stage molecule, but no information exists to evaluate it as an investable catalyst.

How It Works

The mechanism of XEN1720 is not publicly disclosed. Xenon Pharmaceuticals specializes in ion channel modulation for neuroscience, and its known pipeline candidates target voltage-gated sodium channels (NaV) for epilepsy and pain indications. XEN1720 may be an early-stage ion channel modulator, but this is speculative.

Trial Status

No clinical trial records for XEN1720 were found in ClinicalTrials.gov, SecBot's biotech pipeline database, or any SEC filing or press release. The drug name does not appear in any public Xenon Pharmaceuticals pipeline disclosure.

The Two-Sided Case

▲ Bull Case3
Xenon has a strong cash position of roughly $1.25 billion (as of Q2 2026), funding operations into 2029, which supports early discovery work including potential programs like XEN1720.
Xenon's expertise in ion channel modulation and its validated Kv7 platform (azetukalner) could extend to novel preclinical assets.
CEO Ian Mortimer and CFO Thomas Kelly made open-market insider purchases totaling over $1.6 million in September 2026, signaling confidence in the company's pipeline broadly.
▼ Bear Case4
XEN1720 has zero public presence: no clinical trials, no SEC filing mentions, no press releases, and no pipeline listing. It may not be an active development program at all.
Xenon's lead asset azetukalner faces binary risk: Phase 3 X-NOVA2 depression data is due December 2026, and a prior safety-related setback in the depression program has raised investor concerns.
The company raised $650 million in a March 2026 public offering, diluting existing shareholders, and reported a Q3 2026 net loss of $110 million.
Several large institutional holders trimmed or exited positions in Q2 2026, including Wellington Management (trimmed 70.5%) and Holocene Advisors (fully exited).

Upcoming Catalysts

  • Xenon expects topline Phase 3 X-NOVA2 data for azetukalner in major depressive disorder in December 2026.
  • XEN1701 and XEN1120 are advancing to Phase 2 proof-of-concept studies in acute pain (no specific date announced).
  • The FDA is reviewing Xenon's NDA for azetukalner in focal onset seizures (submitted September 2026); a PDUFA date has not been publicly set.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Xenon Pharmaceuticals Inc. 8-K XENE ·Originating report

Sources · 6

Hover a chip for the title
1 rttnews.com2 markets.businessinsider.com3 msn.com4 msn.com5 marketscreener.com6 markets.financialcontent.com